NeoRx Presents Updated Data From Phase I Trial of STR in Breast Cancer

NeoRx has announced the presentation of updated data from an investigator-sponsored Phase I Trial of STR, NeoRx's investigational bone-targeted radiotherapeutic, in patients with advanced breast cancer.

The Phase I dose-escalation study of STR involved six patients with Stage IV breast cancer metastasized to the bone. Patients were administered STR as a single agent followed by autologous blood stem-cell rescue. Two of the six patients remain alive, without progression of their disease up to six years post-transplant. Among the other four patients, the overall median time to disease progression was 10 months. Disease relapse in these four patients occurred in tissues outside the bone.